Farmadipin (nifedipine) oral drops 2% 25 ml.

Description

Farmadipin 25 ml Composition
active substance: nifedipine;

1 ml of solution contains nifedipine in terms of 100% dry matter 20 mg (30 drops);

excipients: polyethylene glycol 400, ethanol 96%.

Farmadipin 25 ml Dosage form.

Oral drops.

Basic physical and chemical properties: transparent yellow or greenish-yellow viscous liquid with a weak alcoholic odor.

Pharmacotherapeutic group. Selective calcium antagonists with a predominant effect on blood vessels. ATX code C08C A05.

Farmadipin 25 ml Pharmacological properties

Pharmacodynamics.

Pharmadipin® exhibits antianginal and antihypertensive effects. Blocks the flow of calcium ions into cardiomyocytes and smooth muscle cells of coronary and peripheral arteries through slow voltage-gated calcium channels of cell membranes. Relaxes vascular smooth muscles, eliminates spasms and dilates coronary and peripheral arteries, reducing peripheral vascular resistance, blood pressure, afterload and myocardial oxygen demand; slightly reduces myocardial contractility, somewhat reduces platelet aggregation.

Pharmacokinetics.

When taken orally, it is well absorbed in the digestive tract, bioavailability is 40-60%. The effect develops especially quickly (after 5-10 minutes) with sublingual administration. Usually, the maximum action is recorded in 30-40 minutes. Food intake does not significantly affect the rate of absorption of the drug. The hemodynamic effect lasts for 4-6 hours. Up to 90% of nifedipine binds to plasma proteins. It is metabolized in the liver and excreted from the body mainly in the form of inactive metabolites. The total clearance of nifedipine is from 0.4 to 0.6 l / kg / h. The half-life is 2-4 hours. In elderly people and patients with cirrhosis of the liver, the metabolism of nifedipine slows down, therefore, their half-life of the drug can be lengthened by almost 2 times, which requires a dose reduction and an increase in the intervals between doses of the drug. In the body, nifedipine is not cumulated. In small amounts, it penetrates the blood-brain and placental barriers, enters breast milk.

Clinical characteristics.

Indications
Arterial hypertension (for the treatment of hypertensive crises).

Contraindications
Acute myocardial infarction (within the first 4 weeks);
cardiogenic shock;
severe aortic and mitral stenosis;
unstable angina;
do not use for the treatment of angina attacks, secondary prevention of myocardial infarction;
decompensated heart failure;
arterial hypotension (systolic blood pressure (BP) below 90 mm Hg);
ventricular tachycardia with an extended QRS complex;
sick sinus syndrome;
Wolff-Parkinson-White (WPW) syndrome, Laun-Ganong-Levine syndrome (LGL);
AV block II and III degrees;
porphyria;
ileostomy, installed after proctocolectomy;
hypersensitivity to nifedipine and other components of the drug;
hypersensitivity to other dihydropyridines;
do not take at the same time as rifampicin.